The persistent lack of diversity in clinical trials has come to the fore as one of the most salient challenges to trial success. Now we are seeing research, policy and industry commitment combine to build unprecedented momentum for impactful change.
Being intentional about diversity is important. Greater diversity in clinical trials has the potential to yield long-term value, by enabling a more accurate understanding and demonstration of efficacy, safety and indication-specific patient populations—insights that can be used to optimize launch and marketing strategy.
This webinar further explores the value of diverse and equitable clinical trials—including the potential downstream issues if diversity is not addressed early on—and how we can leverage tech-enabled, human-centric solutions to take action on FDA guidelines, meet industry commitments and uphold the ethical responsibility to communities for diverse and equitable clinical trials.
